Compare Moderna, Inc. (MRNA) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Moderna, Inc. trades at $59.73 (market cap $23.60B), while Global X NASDAQ 100 Covered Call ETF trades at $17.81. Which is the better fit depends on your goals.
| MRNA | QYLD | |
|---|---|---|
Market Cap | $23.60B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $81.80 | $18.52 |
52-Week Low | $22.36 | $16.46 |
Enterprise Value | $19.70B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
